These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24703118)

  • 21. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
    Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
    World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Focal Laser Ablation and Photodynamic Vascular Therapy with soluble TOOKAD® in the treatment of low risk prostate cancer].
    Domínguez-Escrig JL; Casanova Ramón-Borja J
    Arch Esp Urol; 2016 Jul; 69(6):327-36. PubMed ID: 27416636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial.
    Johnston J; Struss WJ; Black PC
    Urology; 2017 Jun; 104():7-8. PubMed ID: 28342930
    [No Abstract]   [Full Text] [Related]  

  • 24. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
    Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
    J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities.
    Weersink RA; Bogaards A; Gertner M; Davidson SR; Zhang K; Netchev G; Trachtenberg J; Wilson BC
    J Photochem Photobiol B; 2005 Jun; 79(3):211-22. PubMed ID: 15896648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.
    Haider MA; Davidson SR; Kale AV; Weersink RA; Evans AJ; Toi A; Gertner MR; Bogaards A; Wilson BC; Chin JL; Elhilali M; Trachtenberg J
    Radiology; 2007 Jul; 244(1):196-204. PubMed ID: 17507719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An image guided treatment platform for prostate cancer photodynamic therapy.
    Betrouni N; Colin P; Puech P; Villers A; Mordon S
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():370-3. PubMed ID: 24109701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
    Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
    Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
    Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
    Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
    Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
    Plaks V; Koudinova N; Nevo U; Pinthus JH; Kanety H; Eshhar Z; Ramon J; Scherz A; Neeman M; Salomon Y
    Neoplasia; 2004; 6(3):224-33. PubMed ID: 15153334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
    Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
    Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.
    Flegar L; Zacharis A; Aksoy C; Heers H; Derigs M; Eisenmenger N; Borkowetz A; Groeben C; Huber J
    World J Urol; 2022 Jul; 40(7):1645-1652. PubMed ID: 35562598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
    Preise D; Scherz A; Salomon Y
    Photochem Photobiol Sci; 2011 May; 10(5):681-8. PubMed ID: 21258718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy.
    Eggener SE; Coleman JA
    ScientificWorldJournal; 2008 Oct; 8():963-73. PubMed ID: 18836668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.
    Chevalier S; Anidjar M; Scarlata E; Hamel L; Scherz A; Ficheux H; Borenstein N; Fiette L; Elhilali M
    J Urol; 2011 Jul; 186(1):302-9. PubMed ID: 21600602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer?
    Moore CM; Hoh IM; Bown SG; Emberton M
    BJU Int; 2005 Oct; 96(6):754-8. PubMed ID: 16153193
    [No Abstract]   [Full Text] [Related]  

  • 39. Photodynamic therapy for low risk prostate cancer.
    Ritch CR; Punnen S
    BMJ; 2017 Feb; 356():j575. PubMed ID: 28179362
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.
    Bugaj AM
    World J Methodol; 2016 Mar; 6(1):65-76. PubMed ID: 27019798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.